DOCSLIB.ORG

Final Programme and Book of Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Final Programme and Book of Abstracts In Collaboration with: Final programme and book of abstracts BGCSConference.com @BGCSConference #BGCS2016 BGCS 2016 Programme_v6.indd 1 04/05/2016 10:42 I have ovarian cancer. TEST ME for BRCAm. TREAT ME with Lynparza (olaparib). Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum‑sensitive relapsed BRCA‑mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum‑based chemotherapy. LYNPARZATM 50 MG HARD CAPSULES AML): If confirmed while taking Lynparza, treat statin. The efficacy of hormonal contraceptives may (olaparib) PRESCRIBING INFORMATION. Consult appropriately. Where additional anticancer therapy is be reduced if co-administered with olaparib. Caution Summary of Product Characteristics before recommended, discontinue Lynparza. Pneumonitis: and appropriate clinical monitoring recommended prescribing. Interrupt Lynparza treatment and promptly investigate when sensitive CYP3A substrates or substrates as appropriate. Discontinue Lynparza if pneumonitis with a narrow therapeutic margin (e.g. simvastatin, Use: Monotherapy for the maintenance treatment is confirmed. Drug interactions: Consult SmPC cyclosporine, fentanyl, and quetiapine) or P-gb of adult patients with platinum-sensitive relapsed for further details. Not suitable for combination with substrates (e.g. simvastatin, digoxin, colchicine) BRCA-mutated (germline and/or somatic) high grade other anticancer medicinal products. Caution and are combined with olaparib. Appropriate clinical serous epithelial ovarian, fallopian tube or primary close monitoring if vaccines or immunosuppressant monitoring is recommended for patients receiving peritoneal cancer who are in response (complete agents are co-administered. Effect of other this type of medication. Olaparib may increase the response or partial response) to platinum-based drugs on olaparib: Co-administration with strong exposure to substrates of OATPB1 PI Lynparza 50 mg chemotherapy. Presentation: 50 mg olaparib inducers of CYP3A4/5 isoenzymes (e.g. phenytoin, ONC 15 0029 (Based on ONC 15 0022) 04/03/16 RS hard capsules. Dosage and administration: rifampicin, carbamazepine and St John’s Wort) (e.g. bosentan, glibenclamide, repaglinide, statins and Recommended 400mg (eight capsules) twice daily, should be avoided. Efficacy of Olaparib may be valsartan), OCT1, MATE1, MATE2K (e.g. metformin), take at least one hour after food; refrain from food reduced if combined. Olaparib co-administration OCT2 (e.g. serum creatinine), OAT3 (e.g. furosemide preferably for up to 2 hours afterwards. Treatment with strong (e.g. itraconazole, clarithromycin) or and methotrexate), Undesirable events: Consult should start no later than 8 weeks after completion moderate (e.g. ciprofloxacin, diltiazem) CYP3A SmPC for full list of adverse events. Very common: of the final dose of the platinum-containing regimen inhibitors is not recommended. If a strong or nausea, vomiting, diarrhoea, dyspepsia, dysgeusia, and continue until progression of underlying disease. moderate CYP3A inhibitor must be co-administered, decreased appetite, fatigue (including asthenia), Treatment should be initiated and supervised by the dose of olaparib should be reduced. It is also headache, dizziness, anaemia, neutropaenia, a physician experienced in the use of anticancer not recommended to consume grapefruit juice while lymphopaenia, mean corpuscular volume elevation, therapies. Breast cancer susceptibility gene (BRCA) on olaparib therapy. P-gp inhibitors may increase and increase in blood creatinine. Common: mutation (either germline or tumour) needs to be exposure to olaparib. Effect of olaparib on other thrombocytopaenia, upper abdominal pain, stomatitis. confirmed by a validated test prior to treatment. drugs: In particular, caution should be exercised if Legal category: POM. Marketing authorisation Dose adjustments: Treatment interruption and olaparib is administered in combination with any number: EU/1/14/959/001. Basic NHS cost: 448 dose reduction may be considered to manage statin. The efficacy of hormonal contraceptives may Hard Capsules: £3550.Further information is adverse reactions. If a strong or moderate CYP3A be reduced if co-administered with olaparib. Caution available from the Marketing Authorisation inhibitor must be coadministered, the recommended and appropriate clinical monitoring recommended Holder: AstraZeneca UK Ltd., 600 Capability Green, olaparib dose reduction is 150mg twice daily with when sensitive CYP3A substrates or substrates Luton, LU1 3LU. a strong CYP3A inhibitor or 200mg twice daily with with a narrow therapeutic margin (e.g. simvastatin, a moderate CYP3A inhibitor. Renal impairment: LYNPARZA is a trade mark of the AstraZeneca group cyclosporine, fentanyl, and quetiapine) or P-gb of companies. Can be administered in patients with mild renal substrates (e.g. simvastatin, digoxin, colchicine) impairment. Not recommended for use in moderate/ are combined with olaparib. Appropriate clinical 03/2016 severe renal impairment (creatinine clearance <50ml/ monitoring is recommended for patients receiving ONC 15 0029 min) or hepatic impairment.Contraindications: this type of medication. Olaparib may increase the Hypersensitivity to the active substance or to any exposure to substrates of OATPB1 PI Lynparza 50 mg of the excipients. Pregnancy and breast-feeding. ONC 15 0029 (Based on ONC 15 0022) 04/03/16 RS Adverse events should be reported. Warnings and precautions: Haematological (e.g. bosentan, glibenclamide, repaglinide, statins and Reporting forms and information can be toxicity: Treatment should not be started until there valsartan), OCT1, MATE1, MATE2K (e.g. metformin), found at www.mhra.gov.uk/yellowcard. is a full recovery from haematological toxicity OCT2 (e.g. serum creatinine), OAT3 (e.g. furosemide Adverse events should also be reported to caused by previous anticancer therapy. Monthly and methotrexate), Effect of olaparib on other AstraZeneca on 0800 783 0033 monitoring of complete blood count is recommended drugs: In particular, caution should be exercised CONTENTS for first 12 months of treatment. Myelodysplastic if olaparib is administered in combination with any syndrome/Acute Myeloid Leukaemia (MDS/ Date of preparation: April 2016 966,169.011 BGCS 2016 Programme_v6.indd 2 04/05/2016 10:42 1 I have ovarian cancer. Welcome 2 TEST ME Next Meeting 3 for BRCAm. Scientific Programme 4 TREAT ME Invited Speakers 8 with Lynparza (olaparib). Lynparza is indicated as monotherapy for the maintenance General Information 10 treatment of adult patients with platinum‑sensitive relapsed BRCA‑mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum‑based chemotherapy. Venue Floorplans 12 List of Exhibitors and Sponsors 14 LYNPARZATM 50 MG HARD CAPSULES AML): If confirmed while taking Lynparza, treat statin. The efficacy of hormonal contraceptives may (olaparib) PRESCRIBING INFORMATION. Consult appropriately. Where additional anticancer therapy is be reduced if co-administered with olaparib. Caution Summary of Product Characteristics before recommended, discontinue Lynparza. Pneumonitis: and appropriate clinical monitoring recommended Satellite Symposia 19 prescribing. Interrupt Lynparza treatment and promptly investigate when sensitive CYP3A substrates or substrates as appropriate. Discontinue Lynparza if pneumonitis with a narrow therapeutic margin (e.g. simvastatin, Use: Monotherapy for the maintenance treatment is confirmed. Drug interactions: Consult SmPC cyclosporine, fentanyl, and quetiapine) or P-gb of adult patients with platinum-sensitive relapsed for further details. Not suitable for combination with substrates (e.g. simvastatin, digoxin, colchicine) BRCA-mutated (germline and/or somatic) high grade other anticancer medicinal products. Caution and are combined with olaparib. Appropriate clinical Oral Abstracts 20 serous epithelial ovarian, fallopian tube or primary close monitoring if vaccines or immunosuppressant monitoring is recommended for patients receiving peritoneal cancer who are in response (complete agents are co-administered. Effect of other this type of medication. Olaparib may increase the response or partial response) to platinum-based drugs on olaparib: Co-administration with strong exposure to substrates of OATPB1 PI Lynparza 50 mg chemotherapy. Presentation: 50 mg olaparib inducers of CYP3A4/5 isoenzymes (e.g. phenytoin, ONC 15 0029 (Based on ONC 15 0022) 04/03/16 RS hard capsules. Dosage and administration: rifampicin, carbamazepine and St John’s Wort) (e.g. bosentan, glibenclamide, repaglinide, statins and Recommended 400mg (eight capsules) twice daily, should be avoided. Efficacy of Olaparib may be valsartan), OCT1, MATE1, MATE2K (e.g. metformin), Poster Abstracts 31 take at least one hour after food; refrain from food reduced if combined. Olaparib co-administration OCT2 (e.g. serum creatinine), OAT3 (e.g. furosemide preferably for up to 2 hours afterwards. Treatment with strong (e.g. itraconazole, clarithromycin) or and methotrexate), Undesirable events: Consult should start no later than 8 weeks after completion moderate (e.g. ciprofloxacin, diltiazem) CYP3A SmPC for full list of adverse events. Very common: of the final dose of the platinum-containing regimen inhibitors is not recommended. If a strong
Load more

Recommended publications
  • 22Nd European Conference on General Thoracic Surgery ABSTRACTS
    22ND EUROPEAO N C NFERENCE ON GENERAL THORACIC SURGERY COPENHAGEN – DENMARK 2014 22 nd European Conference European onGeneral ABSTRACTS 15 –18June2014 Copenhagen www.ests.org of Thoracic of Thoracic Surgeons SocietyEuropean – Thoracic SurgeryThoracic Denmark 22nd European Conference on General Thoracic Surgery 15 – 18 June 2014 Bella Center, Copenhagen, Denmark 01 ests2014_toc.indd 1 14.05.2014 14:05:18 22nd European Conference on General Thoracic Surgery 2 01 ests2014_toc.indd 2 14.05.2014 14:05:18 Copenhagen – Denmark – 2014 TABLE OF CONTENTS TABLE OF CONTENTS Monday, 16 June 2014 Session I/ Brompton 5 Session II/ Videos 17 Session III/ Pulmonary Non Neoplastic 23 Session IV/ Young Investigators Award 32 Session V/ Pulmonary Neoplastic I 51 Session VI/ Innovative/Experimental 63 Oscar Night Videos 78 Tuesday, 17 June 2014 Session VIII/ Mixed Thoracic I 85 Session IX/ Mixed Thoracic II 97 Session X/ Pulmonary Neoplastic II 109 Session XI/ Videos II 123 Session XII/ Interesting Cases 129 Session XIII/ Oesophagus/Mediastinum 134 Session XIV/ Airway/Transplantation 146 Session XV/ Chest Wall/Diaphragm/Pleura 155 Session XVI/ MITIG – VATS RESECTIONS 166 Posters 178 Nurse Symposium-Oral 332 Nurse Symposium-Posters 342 List of Authors 361 3 01 ests2014_toc.indd 3 14.05.2014 14:05:18 22nd European Conference on General Thoracic Surgery ABSTRACTS 4 02_ests2014.indd 4 14.05.2014 14:07:30 Abstracts 001 - 006 Copenhagen – Denmark – 2014 ABSTRACTS Monday A.M. MONDAY, 16 JUNE 2014 08:30 - 10:30 SESSION I: BROMPTON B-001 ERGON – TRIAL: ERGONOMIC EVALUATION OF SINGLE-PORT ACCESS VERSUS THREE-PORT ACCESS VIDEO-ASSISTED THORACIC SURGERY Luca Bertolaccini1, A.
    [Show full text]
  • Preliminary Programme VERSION 3 MAY 2017
    PRELIMINARY PROGRAMME VERSION 3 MAY 2017 You can register online now CLICK HERE OPPortUNITIES AND CHALLENGES ANNUAL SCIENTIFIC MEETING 28 – 30 June 2017 ICC BIRMINGHAM PLATINUM SPONSOR British Association of Oral and Maxillofacial Surgeons The Royal College Surgeons, 35-43 Lincoln’s Inn Fields, London WC2A 3PE Email: [email protected] Website: www.baoms.org.uk Plan ahead Contact us at: [email protected] +44 1635 262 400 BAOMS Flyer.1.indd 3 3/21/17 2:33 PM BIRMINGHAM 2017 PRELIMINARY PROGRAMME 3 CONTINUING ProFESSIONAL DEVELOPMENT (CPD) CONTENTS This scientific meeting aims to provide attendees with the opportunity to gain up to date knowledge on the latest developments in research, audit, education, surgical techniques, INtroDUCTION clinical patient management and outcomes in the field of oral and maxillofacial surgery. from ThE BAOMS PRESIDEnT This is delivered through seminars led by experts in their field, masterclasses and short papers presenting the latest research and developments. Participants should verify their own attendance record out of the maximum hours 4 available, which have been calculated as follows: Wednesday 28 June CPD hours 5.25 BAOMS COunCIL 2017 Thursday 29 June CPD hours 6.25 Friday 30 June CPD hours 6.25 4 CERTIFicaTES OF ATTENdaNCE Certificates of attendance indicating the CPD hours for the elements of the meeting ExhIBITIOn PLAn & LISTIngS booked by the attendee will be sent by email after the conference. SIGNING THE ATTENdaNCE REGISTER 5 In order to meet the requirements of verifiable CPD attendees should sign in at the Registration Desk on each day that they attend the conference.
    [Show full text]
  • ANNSURG-D-20-01577 Proofs.Pdf
    CE: R.R.; ANNSURG-D-20-01577; Total nos of Pages: 8; ANNSURG-D-20-01577 REVIEW PAPER Electrocautery, Diathermy, and Surgical Energy Devices Are Surgical Teams at Risk During the COVID-19 Pandemic? à à à AQ2 Kimberley Zakka, Simon Erridge, MBBS, BSc, Swathikan Chidambaram, Michael Kynoch,y à à AQ3 James Kinross, and Sanjay Purkayastha Y, on behalf of the PanSurg collaborative group coronavirus disease-19 (COVID-19) pandemic there are understand- Objective: The aim of the study was to provide a rapid synthesis of available able concerns amongst the surgical community as to the risk of viral data to identify the risk posed by utilizing surgical energy devices intra- transmission within such surgical plumes. operatively due to the generation of surgical smoke, an aerosol. Secondarily it To date, live SARS-CoV2 has been detected in lower respira- aims to summarize methods to minimize potential risk to operating room staff. tory tract samples, saliva, feces, bile, and blood specimens.2,3 As Summary Background Data: Continuing operative practice during the such, during the perioperative process, precautions should be con- coronavirus disease-19 (COVID-19) pandemic places the health of operating sidered to minimize potential risk to the clinical team. Similar to the theatre staff at potential risk. SARS-CoV2 is transmitted through inhaled severe acute respiratory syndrome (SARS) and Middle East respira- droplets and aerosol particles, thus posing an inhalation threat even at tory syndrome outbreaks, there is a paucity of data on the potential of considerable distance. Surgical energy devices generate an aerosol of biolog- transmission of the virus intraoperatively.
    [Show full text]
  • EACMFS16 Scientific Programme Monday, September 12, 2016
    EACMFS16 Scientific programme Monday, September 12, 2016 TRAINEE DAY: AOCMF LECTURE - ADVANCES IN COMPUTER-ASSISTED MICROVASCULAR CRANIOMAXILLOFACIAL RECONSTRUCTION 08:00 - 10:00 MOUNTBATTEN 08:00 AOCMF LECTURE - ADVANCES IN COMPUTER-ASSISTED MICROVASCULAR CRANIOMAXILLOFACIAL RECONSTRUCTION TRAINEE DAY: HANDS-ON WORKSHOP I: COMPUTER ASSISTED MICROVASCULAR CRANIO MAXILLO-FACIAL 10:00 - 12:00 CAMBRIDGE 10:00 HANDS-ON WORKSHOP I: COMPUTER ASSISTED MICROVASCULAR CRANIO MAXILLO-FACIAL Chair: Majeed Rana (Germany) TRAINEE DAY: HANDS-ON WORKSHOP II: MECTRON PIEZOSURGERY 10:00 - 12:00 WINDSOR 10:00 HANDS-ON WORKSHOP II: MECTRON PIEZOSURGERY Chair: Manlio Galiè (Italy) Break: LUNCH BREAK IN THE CAMBRIDGE HALL 12:00 - 13:00 CAMBRIDGE TRAINEE DAY: JOHN LOWRY TRAINEE STUDY DAY – FROM THEN UNTIL NOW – MILESTONES OF CRANIOMAXILLOFACIAL SURGERY & RECONSTRUCTION 13:00 - 19:30 MOUNTBATTEN 13:00 WELCOME ADDRESS, INTRODUCTION OF FACULTY, COURSE OBJECTIVES 13:00 Manlio Galiè (Italy) 13:00 Majeed Rana (Germany) 13:00 Ian Martin (United Kingdom) 13:00 Ash Gulati () 13:15 ACADEMIC WRITING Jörg Wiltfang (Germany) 13:45 INTRODUCTION TO CRANIOFACIAL SURGERY: BASIC CONCEPTS AND PRINCIPLES Luigi Clauser (Italy) 13:45 INTRODUCTION TO CRANIOFACIAL SURGERY: BASIC CONCEPTS AND PRINCIPLES Manlio Galiè (Italy) 14:15 PRIMARY ORBITAL RECONSTRUCTION Majeed Rana (Germany) 14:45 SECONDARY ORBITAL RECONSTRUCTION Michael Grant (USA) 15:15 ORTHOGNATIC SURGERY AND DISTRACTION OSTEOGENESIS Manlio Galiè (Italy) 15:45 MILESTONE IN 3D VIRTUAL PLANNING OF ORTHOGNATHIC SURGERY Gwen Swennen (Belgium) 16:15 CRANIOMAXILLOFACIAL RECONSTRUCTION IN CONGENITAL AND ACQUIRED DEFORMATIES Nils-Claudius Gellrich (Germany) 16:45 DISCUSSION AND COFFEE BREAK 17:15 EUROPEAN TRAINEE BUSINESS MEETING 17:15 Majeed Rana (Germany) 17:15 M. Billa (Belgium) 17:45 PERSPECTIVES AND CHALLENGES IN RECONSTRUCTION AFTER ABLATIVE SURGERY Moni Abraham Kuriakose (USA) 18:15 RECONSTRUCTION WITH MYOCUTANEOUS MICROVASCULAR FLAPS Klaus D.
    [Show full text]
  • Sansescofet-Dissertation
    Copyright by Marta Sans Escofet 2020 The Dissertation Committee for Marta Sans Escofet Certifies that this is the approved version of the following Dissertation: Advancements in Ambient Ionization Mass Spectrometry Towards Improved Ovarian Cancer Research and Diagnosis Committee: Livia Schiavinato Eberlin, Supervisor Jennifer S. Brodbelt Richard M. Crooks Robert Tibshirani Advancements in Ambient Ionization Mass Spectrometry Towards Improved Ovarian Cancer Research and Diagnosis by Marta Sans Escofet Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin May 2020 Dedication To my parents, Ramon and Joana Acknowledgements I am extremely grateful for all the opportunities and support I have received during graduate school. It has been a truly exciting and enlightening experience, and I owe that to everyone who has been with me throughout this journey. First of all, I would like to thank my parents, Ramon and Joana, and my sister Mireia for always being my number one fans. Mom and dad, staying close to you despite being 5,000 miles apart has been a source of strength for me every day. Thank you for always being there during my good and bad moments and for your advice and words of encouragement. Your relationship inspires me, I admire everything you have accomplished together for our family with all your hard work. Thank you for teaching me the importance of enjoying everything you do and to live life at the fullest. Love you and miss you very much.
    [Show full text]
  • Official Proceedings
    Scientific Session Awards Abstracts presented at the Society’s annual meeting will be considered for the following awards: • The George Peters Award recognizes the best presentation by a breast fellow. In addition to a plaque, the winner receives $1,000. The winner is selected by the Society’s Publications Committee. The award was established in 2004 by the Society to honor Dr. George N. Peters, who was instrumental in bringing together the Susan G. Komen Breast Cancer Foundation, The American Society of Breast Surgeons, the American Society of Breast Disease, and the Society of Surgical Oncology to develop educational objectives for breast fellowships. The educational objectives were first used to award Komen Interdisciplinary Breast Fellowships. Subsequently the curriculum was used for the breast fellowship credentialing process that has led to the development of a nationwide matching program for breast fellowships. • The Scientific Presentation Award recognizes an outstanding presentation by a resident, fellow, or trainee. The winner of this award is also determined by the Publications Committee. In addition to a plaque, the winner receives $500. • All presenters are eligible for the Scientific Impact Award. The recipient of the award, selected by audience vote, is honored with a plaque. All awards are supported by The American Society of Breast Surgeons Foundation. The American Society of Breast Surgeons 2 2017 Official Proceedings Publications Committee Chair Judy C. Boughey, MD Members Charles Balch, MD Sarah Blair, MD Katherina Zabicki Calvillo, MD Suzanne Brooks Coopey, MD Emilia Diego, MD Jill Dietz, MD Mahmoud El-Tamer, MD Mehra Golshan, MD E. Shelley Hwang, MD Susan Kesmodel, MD Brigid Killelea, MD Michael Koretz, MD Henry Kuerer, MD, PhD Swati A.
    [Show full text]
  • Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales
    Author Manuscript Published OnlineFirst on March 19, 2019; DOI: 10.1158/0008-5472.CAN-18-3411 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Picosecond infrared laser desorption mass spectrometry identifies medulloblastoma subgroups on intrasurgical timescales Michael Woolmana,b,*, Claudia M. Kuzan-Fischerc,h,i,*, Isabelle Ferryc,h,i,*, Taira Kiyotad, Betty Luuc,h,i, Megan Wuc,h,i, David G. Munozf, Sunit Das c,e,f, Ahmed Amand , Michael D. Taylorb,c,e,h,i, James T. Rutkac,e,h,, Howard J. Ginsberga,e,f,g and Arash Zarrine-Afsar a,b,e,f ,** a Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, ON, M5G 1P5, Canada b Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, ON, M5G 1L7, Canada c Peter Gilgan Centre for Research and Learning, Hospital for Sick Children, 686 Bay Street, Toronto, ON, M5G 0A4, Canada d Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Toronto, ON M5G 0A3, Canada e Department of Surgery, University of Toronto, 149 College Street, Toronto, ON, M5T 1P5, Canada f Keenan Research Center for Biomedical Science & the Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada g Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College Street, Toronto, ON, M5S 3G9, Canada h Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto,
    [Show full text]
  • The Inside Story
    MAY 2018 #64 Upfront In My View Feature Sitting Down With Can breast milk help The continuous evolution Wanted: more chemistry First-class pharma scientist, diagnose cancer? of HPLC in the clinic Kelly Zhang 11 18 40 – 43 50 – 51 M4I: The Inside Story Breaking boundaries in mass spectrometry imaging. 22 – 31 www.theanalyticalscientist.com CHANGES EVERYTHING Shimadzu’s LCMS-8060 makes a real difference Outstanding durability to working better and faster. The LCMS-triple- achieving peak area response RSD of quadrupole combines all UF technologies and 3.5 %*, thus showing high robustness pushes the limits of LC-MS/MS quantitation for applications requiring highest sensitivity and robustness. World’s highest sensitivity based on the new UF Qarray technology, deliver ing new limits of MRM sensitivity and impacting full-scan sensitivity Unmatched speed due to data acquisition with scan speed *2,400 samples of femtogram levels of alprazolam spiked of 30,000 u/sec and polarity switching time into protein-precipitated human plasma extracts over a 6 day of 5 msec period (over 400 samples were injected each day). www.shimadzu.eu/lcms-8060 Image of the Month Cheap as Chips Behold: the first ever (working) capillary gel electrophoresis chip made using high-definition inkjet 3D printing. The chip, produced by a team from the Wrocław University of Science and Technology, is capable of separating a 50–800 bp DNA ladder, and its transparency allows it to be used for laser-induced fluorescence detection. While less sensitive than those made with conventional fabrication techniques, the chip is up to 40 times cheaper, and takes hours – rather than days – to produce.
    [Show full text]
  • Logrono Colostate 0053N 16043
    THESIS ASSESSMENT OF METHODS TO SCREEN FOR CAROTENOIDS IN YELLOW-FLESHED POTATO GERMPLASM Submitted by Jeremy Brandon Logrono Department of Horticulture and Landscape Architecture In partial fulfillment of the requirements For the Degree of Master of Science Colorado State University Fort Collins, Colorado Spring 2020 Master’s Committee: Advisor: David G. Holm Co-Advisor: Sastry Jayanty Adam Heuberger Patrick Byrne Copyright by Jeremy Brandon Logrono 2020 All Rights Reserved ABSTRACT ASSESSMENT OF METHODS TO SCREEN FOR CAROTENOIDS IN YELLOW-FLESHED POTATO GERMPLASM Rapid Evaporative Ionization Mass Spectrometry (REIMS) has the capability to rapidly perform tissue analysis without sample preparation, extractions or chromatography required. The study was conducted to evaluate REIMS as an efficient platform to identify carotenoids in yellow-fleshed potato germplasm (N = 60) from the Colorado Potato Breeding and Selection Program. The specific aim eventually is to improve selection efficiency and accelerate genetic gain in nutritional quality of potato cultivars. Phenotypic tuber flesh color (FC) rating (0 – 3), chroma values, and individual and total carotenoids data were collected, processed and combined With multivariate analyses to help in REIMS data interpretation. Results showed that orange- fleshed (FC 3) potato genotypes gave significantly higher overall carotenoid content (P < 0.0001) compared to the white-fleshed (FC 0), yellow-fleshed (FC 1) and dark yellow-fleshed (FC 2) genotypes. Zeaxanthin was the major carotenoid detected among the 60 selections/cultivars evaluated. The association betWeen tuber flesh chroma and carotenoid content was analyzed. Results from Pearson correlation analysis revealed positive correlations overall. The correlation coefficient values (r) for lutein vs. chroma (r = 0.56, P < 0.01), zeaxanthin vs.
    [Show full text]
  • Is the Pen Really Mightier Than the Scalpel? 1Gargi S Sarode, 2Nilookumari Choudhary, 3Sachin C Sarode, 4Shankargouda Patil
    JCDP Is the Pen10.5005/jp-journals-10024-2161 really Mightier than the Scalpel? EDITORIAL Is the Pen really Mightier than the Scalpel? 1Gargi S Sarode, 2Nilookumari Choudhary, 3Sachin C Sarode, 4Shankargouda Patil How to cite this article: Sarode GS, Choudhary N, Sarode SC, There are few other methods by which surgical margin Patil S. Is the Pen really Mightier than the Scalpel? J Contemp assessment can be done. Rapid evaporative ionization Dent Pract 2017;18(11):987-988. mass spectrometry (MS) called iKnife is one of them. It Source of support: Nil includes an electrocauterization device and MS. It allows Conflict of interest: None to rapidly analyze the vital as well as processed tissues, which helps in real-time margin analysis.2 Another important advantage is that this method helps to localize INTRODUCTION lesional tissue including metastases during resection.2 One of the most crucial aspects of cancer diagnosis and But the technology relies on tissue damage to produce treatment is to determine the thin boundary between molecular ions.2-4 Along with this, the major concern lesional and normal tissues. So it is important to assess is that the electrosurgical smoke contains irritants, car- an accurate negative margin and to completely excise the cinogens, and neurotoxic compounds. Exposure to these tumor for a prolonged disease-free state and increase the compounds may cause health hazards.5 overall survival of the patient. Another method is desorption electrospray ionization The conventional method for margin assessment is MS imaging, which is useful for ex vivo cancer diagnosis histopathological analysis, which is labor-intensive, time- and to evaluate surgical margin of tissue sections and intensive, and requires expertise.
    [Show full text]
  • Water-Assisted Laser Desorption/Ionization Mass Spectrometry for Minimally Invasive in Vivo and Real-Time Surface Analysis Using Spidermass
    PROTOCOL https://doi.org/10.1038/s41596-019-0217-8 Water-assisted laser desorption/ionization mass spectrometry for minimally invasive in vivo and real-time surface analysis using SpiderMass Nina Ogrinc 1,6, Philippe Saudemont1,2,6, Julia Balog3, Yves-Marie Robin1,4, Jean-Pascal Gimeno1, Quentin Pascal1,5, Dominique Tierny1,5, Zoltan Takats3, Michel Salzet 1* and Isabelle Fournier 1* Rapid, sensitive, precise and accurate analysis of samples in their native in vivo environment is critical to better decipher physiological and physiopathological mechanisms. SpiderMass is an ambient mass spectrometry (MS) system designed for mobile in vivo and real-time surface analyses of biological tissues. The system uses a fibered laser, which is tuned to excite the most intense vibrational band of water, resulting in a process termed water-assisted laser desorption/ ionization (WALDI). The water molecules act as an endogenous matrix in a matrix-assisted laser desorption ionization (MALDI)-like scenario, leading to the desorption/ionization of biomolecules (lipids, metabolites and proteins). The ejected material is transferred to the mass spectrometer through an atmospheric interface and a transfer line that is several meters long. Here, we formulate a three-stage procedure that includes (i) a laser system setup coupled to a 1234567890():,; 1234567890():,; Waters Q-TOF or Thermo Fisher Q Exactive mass analyzer, (ii) analysis of specimens and (iii) data processing. We also describe the optimal setup for the analysis of cell cultures, fresh-frozen tissue sections and in vivo experiments on skin. With proper optimization, the system can be used for a variety of different targets and applications.
    [Show full text]
  • SAGES-2016-Final-Program.Pdf
    Surgical Spring Week SAGES 2016 Scientific Session & Postgraduate Courses Quality, Innovation & Mastery FINAL PROGRAM PROGRAM CHAIRS: Robert D. Fanelli, MD, MHA Thadeus L. Trus, MD HYNES VETERANS MEMORIAL CONVENTION CENTER, BOSTON, MA MARCH 16-19, 2016 B:8.75” T:8.5” S:8” Proud SAGES Supporter Join us at SAGES 2016 Annual Meeting Visit booth 423 to learn about our surgical solutions. B:11.25” S:10.5” T:11” ©2015 Ethicon US, LLC. All rights reserved. ETHI16LINK0247_MeetingsCnvntns_2016_Sages_Ad_r3.indd 1 1/20/16 11:25 AM Table of Contents 4 General Information 69 FRIDAY, MARCH 18, 2016 7 News, Unique Features, National Quality Strategy Priorities 70 SS09: Foregut 1 8 Hotels & Complex Map, Childcare Options 70 SS10: Miscellaneous MIS 2016 SAGES 10 Schedule at a Glance 71 SS11: Bariatrics 12 Community Service Initiativess & Meeting App Information 71 SS12: Ventral Hernia 13 SAGES Policy on Conflict of Interest 72 SS13: Biliary 14 Meeting Commercial Bias Reporting Form 72 SS14: Hernia Potpourri 15 CME Hours & Accreditation 73 SS15: Plenary 1 16 Self-Assessment CME Credit 73 Presidential Address - Brian Dunkin, MD 16 Learning Themes & Guidelines Info 73 Keynote: Gerald Marks Lecture - Jo Buyske, MD 17 Meeting Leaders 74 Panel: Uh oh! What do I do? Management of Endoscopic Misadventures 19 Webcast Sessions 74 SS16: Foregut 2 21 WEDNESDAY, MARCH 16, 2016 76 SS17: HPB 22 PG Course: Common Bile Duct Stones - IOC to LCBDE 76 SS18: Surgical Education 23 PG Course: Getting Behind Advances in Colorectal Surgery 77 SS19: Robotics 24 PG Course: SAGES
    [Show full text]